Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 with Neoadjuvant Radiotherapy for LARC
NCT05965531Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in rectal cancer, sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate. Started Jan 2024; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05965531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965531.